Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931858 | 0.92 | DRD2 (0.61) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL11562405 | 0.92 | DRD2 (0.61) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL1012326 | 0.91 | DRD2 (0.57) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL6211429 | 0.91 | OPRM1 (0.63) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL11077040 | 0.89 | DRD2 (0.58) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL3290233 | 0.88 | DRD2 (0.57) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL30980941 | 0.87 | DRD2 (0.57) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| Hydrochloric Acid SCHEMBL29398597 | 0.86 | DRD2 (0.56) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| Hydrochloric Acid SCHEMBL7655718 | 0.86 | DRD2 (0.56) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| Hydrochloric Acid SCHEMBL4919274 | 0.86 | DRD2 (0.56) | DRD2SLC6A4OPRM1OPRL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110430901-B | Process for preparing glucuronide drug-linkers and intermediates thereof | 西雅图基因公司 | 2024-08-16 | — | — | CN | claimed |
| CN-110430901-B | Process for preparing glucuronide drug-linkers and intermediates thereof | 西雅图基因公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240207435-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | SEAGEN INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11730822-B2 | Process for the preparation of glucuronide drug-linkers and intermediates thereof | SEAGEN INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20200222553-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | SEATTLE GENETICS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3600443-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | Seattle Genetics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110430901-A | Process for preparing glucuronide drug-linkers and intermediates thereof | SEATTLE GENETICS INC | 2019-11-08 | — | — | CN | disclosed |
| WO-2018175994-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | SEATTLE GENETICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-2595482-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-5434164-A | Carbostyril derivatives and salts thereof and pharmaceutical compositions for inhibiting adhesion of thrombocytes | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0240015-B1 | Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use | OTSUKA PHARMA CO LTD (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5008274-A | Carbostyril derivatives and salts thereof and pharmaceutical composition for inhibiting adhesion of thrombocytes | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0240015-A2 | Carbostyril derivatives, process for preparing them, pharmaceutical composition, and use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730822-B2 | Process for the preparation of glucuronide drug-linkers and intermediates thereof | UGT1A4, UGT1A1, UGT2B7 | DRD2 2148/4885SLC6A4 872/4885OPRM1 1188/4885 |
| US-20240207435-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | UGT1A4, UGT1A1, UGT2B7 | DRD2 2148/4885SLC6A4 872/4885OPRM1 1188/4885 |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | DRD2 4158/4885SLC6A4 2544/4885OPRM1 819/4885 |
| US-20200222553-A1 | PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF | UGT1A4, UGT1A1, UGT2B7 | DRD2 2148/4885SLC6A4 872/4885OPRM1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.